Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK

References

• Key NS, Kasthuri RS. Current treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):1–11. PubMed PMID: 20139364; PubMed Central PMCID: PMCPMC2841004.
   Web of Science ®Google Scholar
• Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756–764. PubMed PMID: 17938798.
   PubMed Web of Science ®Google Scholar
• Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax. 2013 Apr;68(4):391–393. PubMed PMID: 23234857.
   Web of Science ®Google Scholar
• Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J. 2015;13:20. PubMed PMID: 26074735; PubMed Central PMCID: PMCPMC4464718.
   PubMed Web of Science ®Google Scholar
• NICE. Treating venous thromboembolism. NICE pathways. 2016 [cited 2016 May 16]. Available from: http://pathways.nice.org.uk/pathways/venous-thromboembolism#path=view%3A/pathways/venous-thromboembolism/treating-venous-thromboembolism.xml&content=view-node%3Anodes-pharmacological-interventions.
   Google Scholar
• Werdan K, Braun-Dullaeus R, Presek P. Anticoagulation in atrial fibrillation: NOAC’s the word. Dtsch Arztebl Int. 2013 Aug;110(31–32):523–524. PubMed PMID: 24069072; PubMed Central PMCID: PMCPMC3782018.
   Web of Science ®Google Scholar
• Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014 Jul;74(11):1209–1231. PubMed PMID: 25034361; PubMed Central PMCID: PMCPMC4107274.
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406–1415. PubMed PMID: 23991658.
   PubMed Web of Science ®Google Scholar
• NICE. Developing NICE guidelines: the manual. NICE process and methods guides. London; 2015. Available from: https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf
   Google Scholar
• Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014 Sep 2;112(3):598–605. PubMed PMID: 24898545.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997 Jul-Aug;82(4):423–428. PubMed PMID: 9299855.
   PubMed Web of Science ®Google Scholar
• Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004 Apr 26;164(8):880–884. PubMed PMID: 15111374.
   PubMedGoogle Scholar
• Furlan A, Aghayev A, Chang CC, et al. Short-term mortality in acute pulmonary embolism: clot burden and signs of right heart dysfunction at CT pulmonary angiography. Radiology. 2012 Oct;265(1):283–293. PubMed PMID: 22993221; PubMed Central PMCID: PMCPMC3447174.
   Web of Science ®Google Scholar
• Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology. 2006 Apr 25;66(8):1182–1186. PubMed PMID: 16636234.
   PubMed Web of Science ®Google Scholar
• Mayer E, Klepetko W. Techniques and outcomes of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006 Sep;3(7):589–593. PubMed PMID: 16963539.
   Google Scholar
• Saouti N, Morshuis WJ, Heijmen RH, et al. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience. Eur J Cardiothorac Surg. 2009 Jun;35(6):947–52; discussion 952. PubMed PMID: 19272789.
   Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007 Feb;92(2):199–205. PubMed PMID: 17296569.
   PubMed Web of Science ®Google Scholar
• Office of National Statistics. National life tables, UK statistical bulletins. 2013 [cited 2016 Sept 20]. Available from: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/previousReleases
   Google Scholar
• Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a UK national questionnaire survey. BMJ. 1998 Mar 7;316(7133):736–741. PubMed PMID: 9529408; PubMed Central PMCID: PMCPMC28477.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Bauersachs R, Gitt AK, et al. Health state in patients with venous thromboembolism on conventional and non-Vka oral anticoagulants as assessed with the Eq-5d-5l questionnaire: prefer in Vte registry. Value Health. 2014 Nov;17(7):A493–4. PubMed PMID: 27201471.
   Web of Science ®Google Scholar
• Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001 Aug;111(2):130–139. PubMed PMID: 11498067.
   PubMed Web of Science ®Google Scholar
• Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost. 2004 Dec;92(6):1336–1341. PubMed PMID: 15583742.
   PubMed Web of Science ®Google Scholar
• Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR utility index. Eur Respir J. 2008 Dec;32(6):1513–1519. PubMed PMID: 18768576.
   Web of Science ®Google Scholar
• Department of Health. NHS Reference Costs 2015/16. 2016 [cited 2018 22 May 22]. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
   Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014 May;30(5):829–837. PubMed PMID: 24432872.
   PubMed Web of Science ®Google Scholar
• Department of Health. NHS reference costs 2013/14. 2014 [cited 2016 May 16]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380322/01_Final_2013-14_Reference_Costs_publication_v2.pdf.
   Google Scholar
• Goodacre S, Sampson F, Stevenson M, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess. 2006 May;10(15):1–168, iii-iv. PubMed PMID: 16707072.
   Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JS, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009 Feb;33(2):332–338. PubMed PMID: 18829679.
   PubMed Web of Science ®Google Scholar
• Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the UK. Pharmacoeconomics. 2003;21(Suppl 1):43–50. PubMed PMID: 12648034.
   PubMed Web of Science ®Google Scholar
• Preblick R, Kwong WJ, White RH, et al. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. Hosp Pract (1995). 2015;43(5):249–257. PubMed PMID: 26549305.
   PubMedGoogle Scholar
• Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One. 2015;10(12):e0144856. PubMed PMID: 26716830; PubMed Central PMCID: PMCPMC4696796.
   PubMed Web of Science ®Google Scholar
• Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2015 Feb;39(2):155–165. PubMed PMID: 24989022.
   Web of Science ®Google Scholar
• van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–328. PubMed PMID: 24330006.
   PubMed Web of Science ®Google Scholar
• Jugrin AV, Ustyugova AV, Urbich M, et al. The cost-effectiveness of dabigatran etexilate compared with rivaroxaban in the treatment of acute venous thromboembolism in the Uk. Value Health. 2014 Nov;17(7):A489. PubMed PMID: 27201449.
   Web of Science ®Google Scholar
• Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol. 2010 Aug 1;32(4):427–442. PubMed PMID: 19930411.
   PubMed Web of Science ®Google Scholar